ACCESS Newswire·May 13, 2026, 8:00 AM ET

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

MIRA Pharmaceuticals announced the acceptance & publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences describing preclinical findings for its investigational oral drug SKNY-1.
The study utilized an MC4R-deficient zebrafish model to evaluate SKNY-1, a THCV analog, for obesity & nicotine addiction.
Key results included dose-dependent body weight reductions of approximately 30% over six days without significant loss of whole-body density.
Treatment demonstrated lipid normalization characterized by reduced total cholesterol, LDL, & hepatic triglyceride accumulation.
SKNY-1 attenuated compulsive high-calorie feeding & nicotine-seeking behaviors in multiple behavioral paradigms.
The drug modulated appetite-regulatory gene expression patterns for leptin & ghrelin toward wild-type levels.
Pharmacological characterization revealed differential engagement of CB1 pathways, partial agonist activity at CB2, & selective inhibition of MAO-B over MAO-A.
MIRA noted that these are short-term preclinical findings in zebrafish & that mammalian studies, toxicology, & regulatory reviews are required before clinical advancement.
SKNY-1 has not received FDA approval, & its safety & efficacy in humans remain unestablished.